US exempts select Indian drugs from new 100% pharma tariff
In short
The United States said some Indian specialty medicines and their ingredients will not face the new 100% pharma tariff. The zero-tariff rule starts on September 29 for eligible goods, and generics are not included.
This matters for Indian drug exporters and US buyers of rare-disease and nuclear medicines. The full product list and how approvals will work are not fully stated.
What the reporting says
The United States exempted select Indian specialty drugs and ingredients from its new 100% pharmaceutical tariff, with the zero-tariff framework applying from September 29 for eligible goods. The reported exemption covers products for rare diseases and nuclear medicines, while generics are not subject to the new tariff. The immediate impact is clearer access for some imports, but the exact product list and approval process remain partly unspecified.
Why it matters
The United States granted an exemption from its new 100% pharmaceutical tariff for select Indian specialty drugs and related ingredients, with the zero-tariff framework starting September 29 for eligible goods. The reported coverage includes products for rare diseases and nuclear medicines, while generics are excluded from the tariff. This matters for Indian pharma exporters and US importers facing supply and health-need concerns. The exact scope of eligible products and approval mechanics remain unclear.